Navigation Links
OncoSec Medical to Present Data at DNA Vaccines 2012 Conference
Date:12/4/2012

SAN DIEGO, Dec. 04, 2012 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced it will be presenting at the DNA Vaccines 2012 Conference at the Loews Coronado Bay Resort in San Diego, California. OncoSec is a Silver Sponsor of the conference.

(Logo: http://photos.prnewswire.com/prnh/20110314/MM64943LOGO)

The Company will conduct two presentations within the Cancer Immune Therapy Track on Thursday, December 6:

From 11:30 AM-12:00 PM PT, Richard Heller, Ph.D., director of the Frank Reidy Research Center for Bioelectrics at Old Dominion University, will speak on "Gene Electrotransfer for the Enhanced Delivery of Immunomodulating Agents." In this presentation, Dr. Heller will present data on electroporation and delivery of plasmids for cancer immunotherapy, a technology used in OncoSec's ImmunoPulse therapy.    

From 12:00 PM-12:30 PM PT, Adil Daud, M.D., clinical professor of medicine and dermatology and director of the melanoma program at the University of California, San Francisco, will speak on "Clinical Studies of Melanoma Therapy." In this presentation, Dr. Daud will be reviewing previously presented interim data from OncoSec's ongoing Phase II trial for metastatic melanoma for which he is principal investigator.

The DNA Vaccines Conference brings in an array of researchers from all corners of the world to present new cutting-edge discoveries in DNA vaccines that have never before been presented or published at any other meeting. For more information about the conference, please visit: www.bioconferences.com/conferences/dna/index.aspx

About OncoSec Medical Inc.

OncoSec Medical Inc. is a biopharmaceutical company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers. ImmunoPulse and NeoPulse therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives.  OncoSec Medical's core technology is based upon its proprietary use of an electroporation platform to dramatically enhance the delivery and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse) or chemotherapeutic agent (NeoPulse). Treatment of various solid cancers using these powerful and targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while sparing healthy normal tissues during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for ImmunoPulse targeting lethal skin cancers. More information is available at http://www.oncosec.com/.

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE OncoSec Medical Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
2. OncoSec Medical Issues Letter to Shareholders
3. OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
4. OncoSec Establishes Clinical Site for Its Phase II Merkel Cell Carcinoma Trial at University of California San Francisco (UCSF)
5. OncoSec OMS ElectroChemotherapy for Head and Neck Cancer Shows Enhanced Quality of Life in Two Randomized Phase III Studies
6. OncoSec Featured on KTVU-TV News and in San Francisco Chronicle
7. OncoSec to Present at the Rodman & Renshaw 2012 Annual Global Investment Conference
8. OncoSec Granted New Patent from China
9. OncoSec to Present at Upcoming Healthcare and Investor Conferences
10. OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients
11. OncoSec Medical Reports Positive Preliminary Efficacy Results from Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... February 10, 2016 The campaign aims ... 5 years reach the milestone of their 5 th ... ensure 2,50,532 children between the ages of 2 - 5 ... --> The campaign aims to ... reach the milestone of their 5 th birthday   ...
(Date:2/9/2016)... 9, 2016  Insulet Corporation (NASDAQ: PODD ) (Insulet ... technology with its OmniPod ® Insulin ... has been appointed to Insulet,s Board of Directors. With his ... of whom are independent. --> ... and finance experience and a deep knowledge of accounting, financial ...
(Date:2/9/2016)... QGEN ; Frankfurt Prime ... Genomics to develop and promote comprehensive solutions for ... --> QGEN ; Frankfurt Prime Standard: QIA) ... develop and promote comprehensive solutions for next-generation sequencing ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... ... It’s that time of year when most people have forgotten all about their New ... (IAAM), Hall of Fame athlete and Garrison Forest School athletic director since 2005, knows ... of her first decisions when her IAAM two-year presidency began last July was to ...
(Date:2/9/2016)... Albuquerque, NM (PRWEB) , ... February 09, 2016 , ... ... proceeds from its Heart Rate Variability scans throughout the month to the American Heart ... to spot the first signs of heart disease and Health Quest’s INSiGHT Pulse Wave ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... Snowfall4pod Digital, creators of the gContentManager & Distribution Network, today announced the ... and print-on-demand network. , AVALANCHE allows enterprise customers to license and create ...
(Date:2/9/2016)... ... February 10, 2016 , ... The Journal of Pain Research ... playing field .” , As corresponding author Dr John F. Peppin says “Terminology matters, ... diagnose our chronic pain patients. ‘Chronic cancer pain’ and ‘chronic non-cancer pain’ are ...
(Date:2/9/2016)... ... 2016 , ... METTLER TOLEDO has published a new guide ... understanding of the techniques they use so they can more easily spot potential ... and rework to create a leaner overall lab experience. , The new ...
Breaking Medicine News(10 mins):